Business Introduction
GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver £40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centred on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems.
Our diverse portfolio consists of vaccines, specialty medicines, and general medicines.
Through continuous innovation and a dedicated focus on scientific and technical excellence, we strive to develop and launch new, groundbreaking treatments that address critical health challenges.

Position Summary
You will be a trusted field sales professional covering an assigned territory in Taiwan. You will build and maintain professional relationships with hospital, clinic and public health teams. You will share clear, evidence-based information and deliver territory plans that improve patient access. We value curiosity, integrity, collaboration and a growth mindset. This role offers learning, visible career growth and the chance to join GSK in uniting science, technology and talent to get ahead of disease together.

Responsibilities
This role will provide YOU the opportunity to lead key activities to progress YOUR career. These responsibilities include some of the following:

Build and maintain trusted professional relationships with clinicians, clinic managers and public health partners across your territory.
Present clear, evidence-based information and provide educational support to healthcare teams.
Develop and execute territory business plans to meet objectives and improve patient access.
Use local data and customer insight to prioritise customers and identify opportunities.
Work with medical, market access and commercial colleagues to plan and deliver local initiatives and events.
Keep accurate CRM records and report on territory activities while following compliance and budget guidelines.

Why You?
This is an on-site role with regular travel across your assigned territory in Taiwan. You will join a supportive team that invests in learning and career development. You will gain practical experience in customer engagement, business planning and cross-functional collaboration. We welcome applicants from all backgrounds. If you want to grow your career and make a meaningful impact on local health, please apply.

Basic Qualification
We are seeking professionals with the following required skills and qualifications to help us achieve our goals:

Bachelor’s degree in life sciences, healthcare, business or a related field.
Minimum 2 years’ experience in pharmaceutical, medical or healthcare sales or field roles.
Proven ability to build and maintain professional relationships with healthcare teams.
Strong verbal and written communication skills in Mandarin. Functional English for written materials and training.
Right to work in Taiwan and willingness to travel regularly across the territory. Valid Taiwan driver’s license preferred.
Commitment to ethical conduct and a patient-focused approach.

Preferred Qualification
If you have the following characteristics, it would be a plus:

Experience working with hospitals, clinics or public health programmes.
Familiarity with Taiwan’s healthcare system and preventive health programmes.
Proven track record of meeting or exceeding sales or access targets.
Comfortable using CRM systems and digital tools for planning and reporting.
Strong planning and analytical skills to turn customer insight into action.
Collaborative mindset with openness to continuous learning.

How to apply
If this role matches your skills and ambitions, please apply now. Tell us briefly how your experience will help improve patient access and strengthen local health systems. We look forward to hearing from you.

Skills

Customer Centric Selling, Data to Insights, Digital Fluency, Omnichannel, Sales Territory Management, Scientific Literacy

Why GSK?

Uniting science, technology and talent to get ahead of disease together.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. We get ahead of disease by preventing and treating it with innovation in specialty medicines and vaccines. We focus on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases – to impact health at scale.

People and patients around the world count on the medicines and vaccines we make, so we’re committed to creating an environment where our people can thrive and focus on what matters most. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we deliver for patients, shareholders and our people.

We are committed to creating an inclusive workplace and providing equal opportunities for all applicants. We embrace an agile working culture across our roles, so if flexibility is important to you please discuss opportunities with our hiring team. If you need any adjustments to the recruitment process to help you demonstrate your strengths and capabilities, contact [email protected]. Please note this email is for adjustment requests only; for other enquiries please use our standard contact channels.

Important notice to Employment businesses/ Agencies

GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK's commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify's Take

What believers are saying

Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend

Company News

Associated Press

Oct 19th, 2026

FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Yahoo Finance

Oct 15th, 2026

GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

The Reporter

Oct 15th, 2026

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco.

Officials announce $2.9 billion from Merck to expand vaccine and medicine manufacturing in Montco. Company is currently in tax dispute with local district, township. PUBLISHED: October 15, 2026 at 1:32 PM EDT UPDATED: October 15, 2026 at 1:38 PM EDT UPPER GWYNEDD - Governor Josh Shapiro and Pennsylvania Department of Community and Economic Development Secretary Rick Siger announced on Wednesday that the state has secured a $2.9 billion investment from Merck global biopharmaceutical company to expand its operations in Montgomery County by the end of 2030. Pennsylvania is investing $5 million in the company's expansion, which will support the manufacturing of lifesaving products and medicine discovery, according to a statement from Shapiro and Siger. As part of the $2.9 billion commitment, Merck is investing $550 million in ADVANCE, a state-of-the-art robotics and AI-enabled drug research and development facility at its West Point Campus, and the nearby Springhouse Innovation Park R&D facility, which will help the company produce life-saving medicines. "My administration has made life sciences a key part of our economic development strategy here in Pennsylvania, and Merck's major investment in Montgomery County is another major win for the commonwealth," said Shapiro in a statement from his office. "We are proud to partner with Merck as they expand their operations in Montgomery County, advance cutting-edge research and manufacturing, and create new opportunities for thousands of Pennsylvanians. The life sciences industry is booming in Pennsylvania and I am committed to winning more investments like this and making sure our commonwealth remains a national leader in innovation, medicine, and manufacturing." A week earlier, also in Montgomery County, Shapiro and Siger announced that pharma giant GSK will invest more than $800 million to expand its facilities in King of Prussia, establishing a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development and advanced digital capabilities in a single site. Funding from RCAP. Merck received a funding proposal from DCED for a $5 million Redevelopment Assistance Capital Program grant for the first West Point projects. Shapiro and Siger were at Merck's West Point campus Wednesday to help cut the ribbon on the ADVANCE facility. West Point plays a critical role in global public health, manufacturing over 200 million doses of vaccines a year. "Merck's continued investment in Montgomery County is a testament to Pennsylvania's strength as a global hub for life sciences, innovation, and advanced manufacturing," said Siger. "The commonwealth's $5 million RACP investment is helping support projects that will strengthen Merck's operations, advance the development and manufacturing of critical medicines and vaccines, and reinforce our competitive edge in an industry that is extremely important in Pennsylvania." In July, Upper Gwynedd Township officials announced that Merck was developing plans for a new manufacturing facility on their West Point campus, the most recent of several approved and built since the start of the 2020s, including expanding the existing "Building 45" for labs and office space in October 2020, a new "Building 50" of roughly 101,000 square feet of manufacturing space in February 2021, a new "Building 32" for freezer space approved in May 2021, expansion of the proposed "Building 50" in August 2021, and a new "Building 63A" production facility approved in November 2021. Merck also secured approvals in 2024 for a new "Building 41" toward the center of the company's 320-acre complex and in 2025 secured approvals from the township to swap preservation of wetlands on the site for another parcel elsewhere in the region. In September township officials approved the latest plans, for a vaccine manufacturing facility of roughly 75,000 square feet. The company, township, and North Penn School District have also been in a dispute over the firm's tax bill since early May, when Upper Gwynedd's staff asked that township's commissioners to approve a contract for new assessments of two properties township's comprising the West Point campus. In June the district hired a special counsel to handle the matter, and in September the school board created a new fund to keep Merck tax payments separate, saying the company was 'paying in protest' during the dispute. Joining Shapiro and Riger on Wedneday, Rob Davis, chairman and CEO of Merck, said, "The ADVANCE facility represents the future of clinical development at Merck and underscores our continued commitment to addressing the needs of the patients we serve." "This builds on our longstanding presence in Pennsylvania where we're proud to invest in the people, communities and scientific capabilities that will help drive the next generation of medicines," he said.

Seeking Alpha

Oct 14th, 2026

GSK plans more than 1,200 job cuts in Belgium.

GSK plans more than 1,200 job cuts in Belgium. GSK (GSK) plans to cut up to 1,217 jobs in Belgium as part of a proposed restructuring affecting research and development, production, and international support services, according to multiple Belgian media reports. The plan covers 482 white-collar employees and 735 management positions, according to union ABVV Chemie. Production-floor worker positions are reportedly excluded from the proposed reorganization. GSK (GSK) outlined the restructuring at a special works council meeting on Wednesday, October 14. The proposed changes affect GSK Biologicals, the group's vaccine business, according to a local report. GSK (GSK) employs about 8,500 people across its Belgian sites in Wavre, Rixensart and Gembloux. The proposed cuts follow a reduction of more than 400 jobs in Belgium during 2025, mainly through temporary-contract non-renewals and voluntary departure. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

WZUU

Oct 14th, 2026

GSK to cut up to 1,217 jobs in Belgium, L'Echo says.

GSK to cut up to 1,217 jobs in Belgium, L'Echo says. BRUSSELS, Oct 14 (Reuters) - British biopharmaceutical company GSK is planning to cut up to 1,217 jobs from its Belgium locations, Belgian newspaper L'Echo reported on Wednesday. - The company announced the plan to unions earlier on Wednesday - The company and unions did not immediately respond to requests for comment (Reporting by Makini Brice;Editing by Elaine Hardcastle) Now Playing Too Late For Love DEF LEPPARD

GSK

Vaccine Sales

About the job